title: [Transarterial chemoembolization in hepatocellular carcinoma].
abstract: BACKGROUND
  Hepatocelullar carcinoma (HCC) is the fifth most common cancer in the world. It mostly occurs in patients with cirrhosis. In the Czech Republic, about 250 new cases are reported per year. Surgery, i.e. liver resection or transplantation, as the only potentially curable method is possible in 15-20% of them. For the rest, palliative treatment is indicated. This includes ablative methods (radiofrequency ablation, alcoholization), transarterial chemoembolization (TACE), systemic chemotherapy or biological treatment by sorafenib. TACE is method of choice in patients unsuitable for surgery and ablative treatment. Another indication is embolization of HCC before liver transplantation to prevent tumour progression. In combination with other methods, down staging of the tumour and curable treatment afterward is possible.
  
  
  OBJECTIVE
  To assess the outcome of transarterial chemoembolisation in patients with hepatocellular carcinoma.
  
  
  METHODS
  Between 2004-2008 we performed 30 TACE. Of that number, 28 TACE were performed in 20 patients with HCC. We super selectively catheterized the tumour via arteria femoralis and used Doxorubicin with Lipiodol as embolic material. In follow up, we carried out laboratory studies and CT.
  
  
  RESULTS
  We have not noticed any major complications. Post-embolization syndrome with fever, nausea and right upper quadrant pain occurred after 10 TACE (33%). One-, two- and three years survival of the patients was 53%, 40% a 20%.
  
  
  CONCLUSIONS
  TACE is safe method prolonging patients' survival with unresectable HCC. For the correct treatment of HCC, its concentration to cancer centres and the cooperation between multiple specialists is necessary.
authors.affiliation: Klinika transplantacní chirurgie IKEM. mavg@medicon.cz
authors.forename: M
authors.initials: M
authors.lastname: Varga
authors.forename: A
authors.initials: A
authors.lastname: Valsamis
authors.forename: I
authors.initials: I
authors.lastname: Matia
authors.forename: J
authors.initials: J
authors.lastname: Peregrin
authors.forename: E
authors.initials: E
authors.lastname: Honsová
authors.forename: M
authors.initials: M
authors.lastname: Safanda
authors.forename: M
authors.initials: M
authors.lastname: Oliverius
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000628:therapy*; D016461:Chemoembolization, Therapeutic; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality / Q000628:therapy*; D010166:Palliative Care; D015996:Survival Rate
chemical_list: D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin